Cenobamate
- Generic Name
- Cenobamate
- Brand Names
- Ontozry, XCopri, Xcopri 250 Mg Maintenance Pack, Xcopri Titration Pack - 12.5 Mg (14), 25 Mg (14) 28 Count
- Drug Type
- Small Molecule
- Chemical Formula
- C10H10ClN5O2
- CAS Number
- 913088-80-9
- Unique Ingredient Identifier
- P85X70RZWS
- Background
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. The exact mechanism of action has not been described in the literature, though it positively modulates GABA and inhibits voltage gated sodium channels.
Cenobamate was granted FDA approval on 21 November 2019.
- Indication
Cenobamate is indicated for the treatment of partial onset seizures in adults.
- Associated Conditions
- Partial-Onset Seizures
- Associated Therapies
- -
No trials found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath